New and updated preclinical and clinical data presented by biopharma firms at the American Diabetes Association's 82nd Scientific Sessions, including: Biomea, Eli Lilly, Gelesis, Vtv.
Abbott Laboratories Inc. announced U.S. FDA clearance for its next-generation Freestyle Libre 3 continuous glucose monitor (CGM) system for people aged 4 years and older with diabetes. Accuracy of the sensor was evaluated in a non-randomized, multicenter, single-arm study with 100 people on intensive insulin therapy (95, aged 6 years and older). Results from the pivotal trial were released May 31, showing it is the first CGM to demonstrate a mean absolute relative difference (MARD) below 8%, indicating it will be one of the most accurate sensors on the market.
New and updated preclinical and clinical data presented by biopharma firms at the 81st Scientific Sessions of the American Diabetes Association, including: Astrazeneca, Boehringer, Diabetology, Eiger, Eli Lilly, Novo, Remd, Scohia.
New and updated preclinical and clinical data presented by biopharma firms at the American Diabetes Association's 80th Scientific Sessions, including: Cirius, Diasome, Dompé, Hua, Lilly, Mannkind, Novo, Oramed, Vtv, Xeris, Zealand.
RSS
